• Info
  • Insider Ownership

Insider Trading & Ownership of Barbara Gayle Duncan

Location
New York, NY
Summary
The estimated net worth of Barbara Gayle Duncan is at least $1,479,011 dollars as of 02 Mar 2026. Barbara Gayle Duncan is the Director of HALOZYME THERAPEUTICS, INC. and owns shares of HALOZYME THERAPEUTICS, INC. (HALO) stock worth about $1.2M. Barbara Gayle Duncan is the Director of Atea Pharmaceuticals, Inc. and owns shares of Atea Pharmaceuticals, Inc. (AVIR) stock worth about $279.5K.
Signature
/s/ Jeffrey Rona, Attorney-in-Fact
All Insider Reports
All Insider Reports

Notify me when Barbara Gayle Duncan files a new Insider Trading report.

⭐ Subscribe ⭐

Ownership of Barbara Gayle Duncan

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
HALO HALOZYME THERAPEUTICS, INC. Director $1,199,522 01 May 2025
AVIR Atea Pharmaceuticals, Inc. Director $279,489 20 Jun 2025
ADAPY Adaptimmune Therapeutics PLC Director 01 Jul 2022
FUSN Fusion Pharmaceuticals Inc. Director 04 Jun 2024
JNCE Jounce Therapeutics, Inc. Director 03 May 2023
OVID Ovid Therapeutics Inc. Director 26 Feb 2026

Insider Transactions Reported by Barbara Gayle Duncan:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.